EUVIMEDEUVIMED entdecken
Kommentar

Targeting of a New Node in Lipid Metabolism as a Potential Treatment Strategy for ACC

Christopher R LaPensee iD, Gary D Hammer

Endocrinology · 2023

DOI: 10.1210/endocr/bqad003 ↗

Kurz gefasst

Kommentar in der Zeitschrift Endocrinology, 2023. Verfasst von Christopher R LaPensee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48106, USA. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Adrenal Cortex Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumors of the adrenal cortex (ACC) are rare and aggressive with low overall survival (1). Complete surgical removal of the adrenal gland is the main treatment for ACC, but symptoms are usually not found until the cancer is large and metastatic. Only a half of patients are amenable to surgical resection upon diagnosis. Therapeutic options for the treatment of ACC are limited, with the most common chemotherapy regimen including a combination of mitotane, doxorubicin, cisplatin, and/or etoposide. Mitotane is an adrenolytic agent derived from the pesticide dichlorodiphenyltrichloroethane (DDT), and it is the only pharmacological approach approved by the U.S. Food and Drug Administration for the treatment of ACC. Although mitotane and chemotherapy are used to treat ACC, the response rates are low, and discontinuation of mitotane-based therapy is common due to serious adverse effects. Despite over a half century of use, the mechanism of action for mitotane has yet to be completely characterized. Recent studies demonstrate that mitotane dysregulates lipid metabolism (2). Among the cytotoxic mechanisms of mitotane is inhibition of sterol-O-acyl transferase 1 (SOAT1), the enzyme responsible catalyzing the combination of free cholesterol and fatty acids into neutral cholesterol esters. Cholesterol is the precursor of steroid hormones and is stored as an ester in lipid droplets in abundance to meet on-demand needs for steroids. Cholesterol stored in lipid droplets is rapidly hydrolyzed by lipases into free cholesterol that is converted to glucocorticoids during stress adaptation. Prevention of esterification causes an excess of free cholesterol and other fatty acids, which are toxic to many cell types. Given the reliance of adrenocortical cells on high capacity for cholesterol storage to produce large a volume of steroids, it is unsurprising that dysregulation of cholesterol storage by esterification is cytotoxic. Targeted inhibition of cholesterol esterification for treatment of ACC has been explored using other highly specific pharmacological inhibitors of SOAT1 (3). Although these studies showed promise in preclinical settings, they failed to demonstrate efficacy in clinical trials (4).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenocortical CarcinomaAdrenal Cortex NeoplasmsHumansMitotaneLipid MetabolismLipolysisLipid Droplets

Stichwörter der Autor:innen

adrenalcancercholesterollipid

Substanzen

Mitotane

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48106, USA.

ORCID-Profile: Christopher R LaPensee

Zitieren

APA

LaPensee, C. R., & Hammer, G. D. (2023). Targeting of a New Node in Lipid Metabolism as a Potential Treatment Strategy for ACC. Endocrinology. https://doi.org/10.1210/endocr/bqad003

Vancouver

LaPensee CR, Hammer GD. Targeting of a New Node in Lipid Metabolism as a Potential Treatment Strategy for ACC. Endocrinology. 2023. doi:10.1210/endocr/bqad003

BibTeX
@article{LaPensee2023,
  author = {LaPensee, Christopher R and Hammer, Gary D},
  title = {Targeting of a New Node in Lipid Metabolism as a Potential Treatment Strategy for ACC},
  journal = {Endocrinology},
  year = {2023},
  doi = {10.1210/endocr/bqad003}
}
Kostenlos starten →